BIOTRON LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.057 AUD | +1.79% |
|
-17.39% | -41.24% |
| Apr. 05 | Biotron Meets Primary Objectives of Phase Two HIV Trial; Shares Surge 25% | MT |
| Feb. 26 | Biotron Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 9.545 | 39.32 | 51.94 | 32.99 | 42.82 | 23.45 |
| Enterprise Value (EV) 1 | 8.002 | 33.58 | 44.33 | 28.79 | 41.15 | 19.51 |
| P/E ratio | -4.74 x | -22.9 x | -13.5 x | -10.3 x | -15.4 x | -6.11 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 5.88 x | 36.6 x | 64.7 x | 22.6 x | 27.5 x | 16.4 x |
| EV / Revenue | 4.93 x | 31.3 x | 55.2 x | 19.7 x | 26.4 x | 13.6 x |
| EV / EBITDA | -5.01 x | -19.9 x | -12.2 x | -9.02 x | -14.9 x | -5.42 x |
| EV / FCF | -6.24 x | -33.7 x | -24.8 x | -12.9 x | -29.8 x | -9.57 x |
| FCF Yield | -16% | -2.97% | -4.03% | -7.73% | -3.36% | -10.5% |
| Price to Book | 7.45 x | 7.23 x | 7.45 x | 8.54 x | 39.2 x | 7.39 x |
| Nbr of stocks (in thousands) | 502,417 | 595,706 | 701,933 | 701,933 | 701,933 | 901,945 |
| Reference price 2 | 0.0190 | 0.0660 | 0.0740 | 0.0470 | 0.0610 | 0.0260 |
| Announcement Date | 8/29/18 | 8/28/19 | 8/27/20 | 8/27/21 | 8/19/22 | 8/25/23 |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Juni | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1.623 | 1.073 | 0.803 | 1.462 | 1.559 | 1.431 |
| EBITDA 1 | -1.599 | -1.688 | -3.626 | -3.192 | -2.769 | -3.602 |
| EBIT 1 | -1.61 | -1.701 | -3.64 | -3.204 | -2.779 | -3.608 |
| Operating Margin | -99.24% | -158.55% | -453.31% | -219.19% | -178.32% | -252.08% |
| Earnings before Tax (EBT) 1 | -1.594 | -1.612 | -3.576 | -3.194 | -2.781 | -3.493 |
| Net income 1 | -1.594 | -1.612 | -3.576 | -3.194 | -2.781 | -3.493 |
| Net margin | -98.22% | -150.24% | -445.31% | -218.5% | -178.44% | -244.03% |
| EPS 2 | -0.004012 | -0.002881 | -0.005466 | -0.004550 | -0.003962 | -0.004255 |
| Free Cash Flow 1 | -1.282 | -0.9958 | -1.787 | -2.226 | -1.383 | -2.04 |
| FCF margin | -79.01% | -92.82% | -222.58% | -152.23% | -88.72% | -142.5% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/29/18 | 8/28/19 | 8/27/20 | 8/27/21 | 8/19/22 | 8/25/23 |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 1.54 | 5.74 | 7.62 | 4.2 | 1.66 | 3.94 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -1.28 | -1 | -1.79 | -2.23 | -1.38 | -2.04 |
| ROE (net income / shareholders' equity) | -117% | -48% | -57.6% | -59% | -112% | -164% |
| ROA (Net income/ Total Assets) | -54.7% | -28.4% | -33.3% | -33% | -55.7% | -74.7% |
| Assets 1 | 2.913 | 5.668 | 10.75 | 9.692 | 4.99 | 4.679 |
| Book Value Per Share 2 | 0 | 0.0100 | 0.0100 | 0.0100 | 0 | 0 |
| Cash Flow per Share 2 | 0 | 0.0100 | 0.0100 | 0.0100 | 0 | 0 |
| Capex | - | 0.04 | - | 0.01 | - | - |
| Capex / Sales | - | 3.82% | - | 0.39% | - | - |
| Announcement Date | 8/29/18 | 8/28/19 | 8/27/20 | 8/27/21 | 8/19/22 | 8/25/23 |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -41.24% | 33.14M | |
| -3.09% | 102B | |
| +1.05% | 96.29B | |
| +1.78% | 22.18B | |
| -15.78% | 21.2B | |
| -9.58% | 18.31B | |
| -38.74% | 17.38B | |
| -13.48% | 16.36B | |
| +6.57% | 13.97B | |
| +33.68% | 12.17B |
- Stock Market
- Equities
- BIT Stock
- Financials Biotron Limited
